PRLD on Nasdaq
Prelude Therapeutics Inc
American pharmaceutical preparations company, incorporated in Delaware.
Price unavailable
Last updated Oct 18, 2026.
Overview
Compare with Emmaus Life Sciences, Inc., Spero Therapeutics, Inc. or Jaguar Health, Inc., or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
-861.3%Operating margin3
-819.6%Net margin3
73.4%Revenue growth, 20253
-145.0%Return on equity3
-$56.4MFree cash flow3
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Research and development100¢$94.3M
Out of $12.1M in revenue.3 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Revenue | $12.1M | $7.0M |
| Research and development | $94.3M | $118.0M |
| General and administrative | $22.4M | $28.7M |
| Total operating expenses | $116.7M | $146.7M |
| Loss from operations | -$104.6M | -$139.7M |
| Other income, net | $5.1M | $12.5M |
| Net loss | -$99.5M | -$127.2M |
| Net loss per share of common stock, basic | -$1.29 | -$1.68 |
| Net loss per share of common stock, diluted | -$1.29 | -$1.68 |
| Weighted average common shares outstanding, basic | 77.0M shares | 75.8M shares |
| Weighted average common shares outstanding diluted | 77.0M shares | 75.8M shares |
| Unrealized (loss) on marketable securities, net of tax | -$27.0K | -$188.0K |
| Comprehensive loss | -$99.5M | -$127.4M |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $35.3M | $12.5M | |
| Marketable securities | $68.0M | $121.1M | |
| Prepaid expenses and other current assets | $2.5M | $2.3M | |
| Total current assets | $105.7M | $135.9M | |
| Restricted cash | $3.2M | $4.0M | |
| Property and equipment, net | $5.1M | $6.8M | |
| Right-of-use asset | $27.2M | $28.7M | |
| Prepaid expenses and other non-current assets | $110.0K | $110.0K | |
| Total assets | $141.3M | $175.5M | |
| Accounts payable | $4.0M | $7.7M | |
| Accrued expenses and other current liabilities | $12.5M | $15.2M | |
| Deferred revenue | $33.7M | $0 | |
| Operating lease liability | $2.7M | $2.5M | |
| Finance lease liability | $0 | $208.0K | |
| Total current liabilities | $53.0M | $25.6M | |
| Deferred revenue, net of current portion | $1.8M | $0 | |
| Other liabilities | $2.8M | $3.1M | |
| Operating lease liability | $15.0M | $15.3M | |
| Total liabilities | $72.7M | $44.1M | |
| Additional paid-in capital | $751.7M | $715.0M | |
| Accumulated other comprehensive income | $8.0K | $35.0K | |
| Accumulated deficit | -$683.1M | -$583.6M | |
| Total stockholders equity | $68.6M | $131.5M | $237.1M |
| Total liabilities and stockholders equity | $141.3M | $175.5M |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $35.3M | $12.5M | |
| Marketable securities | $68.0M | $121.1M | |
| Prepaid expenses and other current assets | $2.5M | $2.3M | |
| Total current assets | $105.7M | $135.9M | |
| Restricted cash | $3.2M | $4.0M | |
| Property and equipment, net | $5.1M | $6.8M | |
| Right-of-use asset | $27.2M | $28.7M | |
| Prepaid expenses and other non-current assets | $110.0K | $110.0K | |
| Total assets | $141.3M | $175.5M | |
| Accounts payable | $4.0M | $7.7M | |
| Accrued expenses and other current liabilities | $12.5M | $15.2M | |
| Deferred revenue | $33.7M | $0 | |
| Operating lease liability | $2.7M | $2.5M | |
| Finance lease liability | $0 | $208.0K | |
| Total current liabilities | $53.0M | $25.6M | |
| Deferred revenue, net of current portion | $1.8M | $0 | |
| Other liabilities | $2.8M | $3.1M | |
| Operating lease liability | $15.0M | $15.3M | |
| Total liabilities | $72.7M | $44.1M | |
| Additional paid-in capital | $751.7M | $715.0M | |
| Accumulated other comprehensive income | $8.0K | $35.0K | |
| Accumulated deficit | -$683.1M | -$583.6M | |
| Total stockholders equity | $68.6M | $131.5M | $237.1M |
| Total liabilities and stockholders equity | $141.3M | $175.5M |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$99.5M | -$127.2M |
| Depreciation and amortization | $1.7M | $1.8M |
| Noncash lease expense | $1.5M | $1.6M |
| Stock-based compensation | $11.9M | $21.3M |
| Amortization of premium and discount on marketable securities, net | -$371.0K | -$4.6M |
| Prepaid expenses and other current assets | -$197.0K | $373.0K |
| Accounts payable | -$3.9M | $3.3M |
| Accrued expenses and other liabilities | -$3.0M | -$808.0K |
| Deferred revenue | $35.5M | $0 |
| Long-term prepaid expenses and other long-term assets | $0 | $295.0K |
| Operating lease liabilities | -$28.0K | $1.1M |
| Net cash used in operating activities | -$56.3M | -$102.9M |
| Purchases of marketable securities | -$100.9M | -$52.7M |
| Proceeds from maturities of marketable securities | $154.4M | $143.6M |
| Purchases of property and equipment | -$67.0K | -$764.0K |
| Net cash provided by investing activities | $53.5M | $90.2M |
| Proceeds from issuance of common stock in connection with the Securities Purchase Agreement | $24.9M | $0 |
| Payment of offering costs | $0 | -$110.0K |
| Proceeds from issuance of common stock in connection with the exercise of stock options | $16.0K | $60.0K |
| Proceeds from the issuance of common stock under ESPP | $150.0K | $379.0K |
| Payment of withholding taxes related to stock-based compensation to employees | -$17.0K | -$54.0K |
| Principal payments on finance lease | -$208.0K | -$395.0K |
| Net cash provided by (used in) financing activities | $24.8M | -$120.0K |
| Net increase (decrease) in cash and cash equivalents | $22.0M | -$12.8M |
| Property and equipment in accounts payable | $0 | $10.0K |
| Unrealized loss on marketable securities | -$27.0K | -$188.0K |
| Offering costs in accounts payable and accrued expenses and other current liabilities | $234.0K | $0 |
No quarter-by-quarter statement was filed.
Leadership
Who has led Prelude Therapeutics Inc, and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
2025
- Chief executive officerKrishna Vaddi Sep 24, 2020 to now11
- PresidentJane Huang Apr 6, 2022 to now12
- PresidentKrishna Vaddi Sep 24, 2020 to Dec 14, 202111
- Chief financial officerBryant David Lim May 16, 2024 to now13
- Chief financial officerLaurent Chardonnet Dec 1, 2021 to Mar 4, 202414
- Chief financial officerBrian Piper Sep 24, 2020 to Aug 27, 202115
Board members and other officers (20)
- Chief Business OfficerSean P. Brusky Mar 19, 2026 to now16
- Chief Medical OfficerCharles Q. Morris Apr 15, 2026 to now17
- EVP, Head of ChemistryAndrew Combs Sep 24, 2020 to now18
- EVP and Chief of Business OperChristopher Pierce Sep 24, 2020 to Sep 7, 202119
- Chief Medical OfficerDavid J. Mauro Sep 24, 2020 to Oct 6, 202120
- EVP, Chief of Clinical AffairsDeborah Morosini Sep 24, 2020 to Feb 17, 202221
- Chief Scientific OfficerPeggy Scherle Sep 24, 2020 to now22
- Board memberPaul C. Scherer Jun 13, 2025 to now23
- Board memberKatina Dorton Oct 20, 2025 to now24
- Board memberMartin Babler Jul 20, 2021 to now25
- Board memberDavid P. Bonita Sep 24, 2020 to now26
- Board memberFelix Baker Sep 24, 2020 to now27
- Board memberJulian Baker Sep 24, 2020 to now27
- Board memberKelvin Neu Sep 24, 2020 to Sep 24, 202028
- Board memberKrishna Vaddi Sep 24, 2020 to now11
- Board memberL.p. 667 Sep 24, 2020 to now27
- Board memberMardi Dier Sep 24, 2020 to now29
- Board memberPaul A. Friedman Sep 24, 2020 to now30
- Board memberVictor Sandor Sep 24, 2020 to now31
- General counselBryant David Lim Feb 22, 2023 to now32
Former names
- Prelude Therapeutics Inc.Jul 11, 2016 to Oct 20, 20172
Timeline
- Sep 24, 2020New chief executive Krishna Vaddi becomes CEO11
Filings
264 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 58 major events, 117 insider forms, 24 large holders, 45 other. The latest 20:
- Sep 10, 20268-K EDGAR
- Aug 11, 202610-Q EDGAR
- Aug 11, 20268-K EDGAR
- Jul 8, 2026SCHEDULE 13G EDGAR
- Jun 10, 20264 PRIMARY DOCUMENT EDGAR
- Jun 10, 20264 PRIMARY DOCUMENT EDGAR
- Jun 10, 20264 PRIMARY DOCUMENT EDGAR
- Jun 10, 20264 PRIMARY DOCUMENT EDGAR
- Jun 10, 20264 PRIMARY DOCUMENT EDGAR
- Jun 10, 20264 EDGAR
- Jun 10, 20268-K EDGAR
- May 12, 202610-Q EDGAR
- May 12, 20268-K EDGAR
- May 4, 20264 PRIMARY DOCUMENT EDGAR
- Apr 29, 2026ARS EDGAR
- Apr 29, 2026DEFA14A EDGAR
- Apr 29, 2026DEF 14A EDGAR
- Apr 28, 2026SCHEDULE 13G EDGAR
- Apr 28, 20264 EDGAR
- Apr 28, 20263 EDGAR
The 264 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last three years, summarized. The full record is on SEC EDGAR.
Insider trades and holders
Large holders
Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 24 such filings since October 2021, the latest 10:
- Jul 8, 2026SCHEDULE 13G
- Apr 28, 2026SCHEDULE 13G
- Apr 23, 2026SCHEDULE 13D/A
- Apr 22, 2026SCHEDULE 13D/A
- Feb 13, 2026SCHEDULE 13G/A
- Nov 7, 2025SCHEDULE 13G
- Jun 13, 2025SCHEDULE 13D/A
- May 15, 2025SCHEDULE 13G/A
- Feb 14, 2025SCHEDULE 13G/A
- Feb 13, 2025SCHEDULE 13G/A
From Forms 4 and Schedules 13D and 13G filed with the SEC.
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 75. Change is in shares since the quarter before.
13F reports cover disclosed long positions in U.S. stocks only.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12SEC EDGARJane Huang, President
- 13
- 14
- 15SEC EDGARBrian Piper, Chief financial officer
- 16
- 17
- 18SEC EDGARAndrew Combs, EVP, Head of Chemistry
- 19
- 20
- 21
- 22
- 23SEC EDGARPaul C. Scherer, Board member
- 24SEC EDGARKatina Dorton, Board member
- 25SEC EDGARMartin Babler, Board member
- 26SEC EDGARDavid P. Bonita, Board member
- 27SEC EDGARFelix Baker, Board member
- 28SEC EDGARKelvin Neu, Board member
- 29SEC EDGARMardi Dier, Board member
- 30SEC EDGARPaul A. Friedman, Board member
- 31SEC EDGARVictor Sandor, Board member
- 32SEC EDGARBryant David Lim, General counsel